- Home
- INTR vs ACAD Comparison
INTR vs ACAD Comparison
Compare INTR & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTR
- ACAD
- Stock Information
- Founded
- INTR 1994
- ACAD 1993
- Country
- INTR Brazil
- ACAD United States
- Employees
- INTR N/A
- ACAD N/A
- Industry
- INTR
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- INTR
- ACAD Health Care
- Exchange
- INTR Nasdaq
- ACAD Nasdaq
- Market Cap
- INTR 2.5B
- ACAD 2.5B
- IPO Year
- INTR N/A
- ACAD 2004
- Fundamental
- Price
- INTR $7.14
- ACAD $17.44
- Analyst Decision
- INTR Buy
- ACAD Buy
- Analyst Count
- INTR 4
- ACAD 15
- Target Price
- INTR $6.48
- ACAD $24.21
- AVG Volume (30 Days)
- INTR 2.3M
- ACAD 1.8M
- Earning Date
- INTR 05-16-2025
- ACAD 05-07-2025
- Dividend Yield
- INTR 1.13%
- ACAD N/A
- EPS Growth
- INTR 176.00
- ACAD N/A
- EPS
- INTR 0.33
- ACAD 1.37
- Revenue
- INTR $743,862,312.00
- ACAD $996,283,000.00
- Revenue This Year
- INTR $84.15
- ACAD $13.07
- Revenue Next Year
- INTR $15.63
- ACAD $10.06
- P/E Ratio
- INTR $21.24
- ACAD $12.74
- Revenue Growth
- INTR 43.28
- ACAD 22.42
- 52 Week Low
- INTR $3.88
- ACAD $13.40
- 52 Week High
- INTR $7.84
- ACAD $20.68
- Technical
- Relative Strength Index (RSI)
- INTR 74.24
- ACAD 67.70
- Support Level
- INTR $6.34
- ACAD $14.45
- Resistance Level
- INTR $7.20
- ACAD $15.31
- Average True Range (ATR)
- INTR 0.23
- ACAD 0.69
- MACD
- INTR 0.05
- ACAD 0.37
- Stochastic Oscillator
- INTR 89.24
- ACAD 94.92
About INTR Inter & Co. Inc.
Inter & Co Inc operates as a digital bank. The company's segment includes Banking & Spending; Investments; Insurance Brokerage; and Inter Shop & Commerce Plus. It generates maximum revenue from the Banking & Spending.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.